Approximately 96 million American adults have prediabetes — and most do not know it. Without intervention, about 15–30% of people with prediabetes will develop type 2 diabetes within 5 years. GLP-1 medications offer a potentially transformative intervention, combining significant weight loss with direct metabolic effects that directly address the root causes of prediabetes.
What Is Prediabetes?
Prediabetes is diagnosed when blood sugar levels are higher than normal but not yet high enough for a type 2 diabetes diagnosis. The standard diagnostic criteria are:
How GLP-1 Medications Address Prediabetes
GLP-1 medications address prediabetes through multiple mechanisms simultaneously:
- Weight Loss
The single most powerful intervention for prediabetes is significant weight loss. Every 1 kg of body weight lost reduces diabetes risk by approximately 16% in at-risk individuals. Patients on GLP-1 medications lose 12–22% of body weight on average — an amount that can fundamentally change metabolic trajectory.
- Improved Insulin Sensitivity
GLP-1 medications directly improve how cells respond to insulin — independent of their weight loss effect. This means blood sugar regulation improves even before significant weight loss occurs.
- Reduced Post-Meal Blood Sugar Spikes
By slowing gastric emptying, GLP-1 medications reduce the rate of glucose absorption after meals — flattening the blood sugar response that is particularly elevated in prediabetes.
- Enhanced Insulin Secretion
GLP-1 medications stimulate insulin secretion in a glucose-dependent manner — meaning the pancreas releases more insulin when blood sugar is high, and less when it is normal. This directly corrects the impaired insulin response characteristic of prediabetes.
What the Clinical Evidence Shows
In the STEP trials for semaglutide, patients with prediabetes at baseline showed significant A1C improvements — with a substantial proportion returning to normoglycemia (normal blood sugar) after 68 weeks of treatment. The SURMOUNT trials for tirzepatide showed even more dramatic metabolic improvements, with many patients reversing pre-diabetic markers entirely.
The SELECT trial (2023) demonstrated that semaglutide reduced major adverse cardiovascular events in high-risk patients — many of whom had prediabetes or metabolic syndrome. This established GLP-1 medications not just as weight loss drugs, but as metabolic and cardiovascular intervention tools.
The clinical picture is increasingly clear: for patients with prediabetes who are overweight, GLP-1 medications may represent the most effective available intervention for preventing progression to type 2 diabetes while simultaneously improving cardiovascular outcomes.
Does Having Prediabetes Help You Qualify?
Yes. Prediabetes qualifies as a "weight-related health condition" under the FDA's eligibility criteria for Wegovy and Zepbound. This means patients with a BMI of 27 or higher and prediabetes may qualify for GLP-1 weight loss treatment. A provider review of your complete health history determines your specific eligibility.